Harry Welten, MBA, spent more than twenty years in international senior executive functions, sixtee of which as chief financial officer in biotechnology companies (privately as well as publicly held).He was involved in IPO’s, mergers and acquisitions and raised more than CHF 320 million from private and public investors. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York.
He serves as Chairman of the Board of Directors of Novaremed AG as well as of BiognoSYS AG, and is a member of the Board of Directors of Kanyos, ASIT Biotech, ProteoMediX, Virometix and Horizon Pharma AG. Harry is also a member of the foundation council of HBM Fondation.